Die Frage, klar formuliert
Consent to a drug is consent to something you can stop. Consent to a permanent gene edit is different: there is no way to undo it if you change your mind or if a problem appears in fifteen years. Add that the biology is unfamiliar, that patients are often severely ill and out of alternatives, and that follow-up commitments run for years, and ordinary consent processes are being asked to do something they were not designed for.
Informed consent for gene-editing therapy must convey permanence, incomplete long-term safety data, distinct risks of conditioning regimens where used, the practical impossibility of withdrawal after administration, and long-term follow-up obligations often lasting 15 years. Complications include therapeutic misconception in early-phase trials, the vulnerability of patients with no remaining options, assent processes for adolescents, and the difficulty of conveying probabilistic genetic information to people with varying numeracy and health literacy.
The arguments
- Patients with severe disease are capable of weighing serious risk and are entitled to do so.
- Paternalistic restriction denies autonomy to exactly the people with most at stake.
- Consent processes for transplantation already handle permanence and serious risk.
- Long-term registries provide the follow-up that makes future consent better informed.
- 'Informed' is hard to achieve when the mechanism is unfamiliar and long-term effects are unknown even to investigators.
- Therapeutic misconception is well documented: early-phase participants frequently expect benefit that the trial is not designed to provide.
- Desperation compromises voluntariness in ways consent forms do not capture.
- Adolescents can assent but not consent, and permanent changes will outlast the parental decision by decades.
Where the science actually stands
Long-term follow-up, typically 15 years, is a standard regulatory expectation for gene-therapy products. Therapeutic misconception in early-phase trials is well documented. There is no consensus on how to convey permanence and deep uncertainty adequately, and consent processes for these therapies remain an active area of research.
Unresolved questions
- How to convey irreversibility in a way people genuinely internalise.
- How to handle consent for children and adolescents facing lifelong consequences.
- What is owed to participants if a problem emerges years later.
Sources
- U.S. Food and Drug Administration · 2020
Long term follow-up after administration of human gene therapy products ↗